Clinical Trial: NCT05805501
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-08-10 |
Study Overview
Brief Summary
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Official Title
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Conditions
Renal Cell Carcinoma
Intervention / Treatment
- Drug: Tobemstomig
- Drug: Tiragolumab
- Drug: Pembrolizumab
- Drug: Axitinib
Other Study ID Numbers
- BO43936
Start Date (Actual)
2023-04-21
Primary Completion Date (Estimated)
2026-10-08
Study Completion Date (Estimated)
2026-10-08
Enrollment (Actual)
199
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-08-10 |
Study Overview
Brief Summary
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Official Title
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Conditions
Renal Cell Carcinoma
Intervention / Treatment
- Drug: Tobemstomig
- Drug: Tiragolumab
- Drug: Pembrolizumab
- Drug: Axitinib
Other Study ID Numbers
- BO43936
Start Date (Actual)
2023-04-21
Primary Completion Date (Estimated)
2026-10-08
Study Completion Date (Estimated)
2026-10-08
Enrollment (Actual)
199
Study Type
Interventional
Phase
Phase 2